Management of myeloma with bisphosphonates
Article Abstract:
Patients with multiple myeloma may benefit from drug therapy that inhibits bone resorption. The bisphosphonates etidronate, clodronate, and pamidronate have been tested in multiple myeloma patients with bone complications. Pamidronate appears to be the most potent inhibitor of bone resorption, according to a 1996 study. Pamidronate reduced skeletal fractures and pain significantly after nine months of therapy. In view of very early bone loss in multiple myeloma, pamidronate should be started in all patients at an early stage. Benefits of pamidronate may extend from stronger bone structures to possibly a longer survival, thought to be a result of a decrease in cancer growth. Other inhibitors of bone resorption also show promise for the future treatment of multiple myeloma, including alternative bisphosphonates, gallium nitrate, and paclitaxel.
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 1996
User Contributions:
Comment about this article or add new information about this topic:
Multiple myeloma
Article Abstract:
Multiple myeloma is a type of cancer characterized by the accumulation of plasma cells in bone marrow. These cells produce immunoglobulins, typically IgG or IgA. The exact cause of multiple myeloma is not known but it appears to have a genetic component. Death usually occurs from the complications of the disease, which include persistent bacterial infections, anemia, bone lesions and kidney failure. The most effective chemotherapy consists of melphalan, cyclophosphamide and prednisone. Interferon alpha is sometimes used to maintain the response to chemotherapy.
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 1997
User Contributions:
Comment about this article or add new information about this topic:
Bisphosphonates in the treatment of bone diseases
Article Abstract:
Bisphosphonates, such as clodronate, pamidronate, or ibandronate, inhibit bone turnover and may represent a viable alternative to estrogen-replacement therapy in women with osteoporosis. These drugs also prevent bone complications associated with cancer or Paget's disease. A 1996 study on breast cancer patients yielded good results with pamidronate without prolonging survival. Skeletal complications and fractures were delayed in the group taking pamidronate. The new drug risedronate may practically prevent bone loss in breast cancer.
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 1996
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Options increase in mental health. The role of lithium clinics in the treatment of bipolar disorder. Early perceptions of the role of community matrons
- Abstracts: Comparison of 1% and 2.5% selenium sulfide in the treatment of tinea capitis. Asymptomatic Dermatophyte Carriers in the Households of Children With Tinea Capitis
- Abstracts: Monitored outpatient management of mild gestational hypertension remote from term in teenage pregnancies. Maternal and perinatal outcome in women with a history of stroke
- Abstracts: Bacteremia with Streptococcus pneumoniae: implications for therapy and prevention. Minimizing the impact of drug-resistant Streptococcus pneumoniae (DRSP): a strategy from the DRSP Working Group
- Abstracts: Untangling the persistence of syphilis in the South. Strategies for syphilis prevention in the 1990s. Approaches to screening and antibiotic use for syphilis prevention